Immunome Inc.
IMNM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001472012
In the last 90 days, Immunome Inc. insiders filed 0 open-market purchases and 7 sales; 202 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Immunome Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 30 | 35 | +5 |
| Shares | 1.86M | 1.95M | +88.9K (+4.8%) |
| Value | $9.34M | $15.4M | +$6.08M (+65.1%) |
New holders (5)
Institutions that held Immunome Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Point72 Asset Management, L.P. | 418,127 | $3.31M | 0.01% |
| Heron Bay Capital Management | 13,139 | $103.9K | 0.03% |
| FNY Investment Advisers, LLC | 3,500 | $27.0K | 0.03% |
| JPMorgan Chase & Co | 915 | $7.24K | 0.00% |
| Cutler Group LP | 600 | $4.00K | 0.00% |
Sold out (0)
Institutions that held Immunome Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
None.